SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin concludes USFDA inspection at Aurangabad facility with one observation

31 Jul 2017 Evaluate

Lupin has successfully completed a PAI inspection (Prior Approval Inspection) carried out by the United States Food and Drug Administration (USFDA) at its Aurangabad manufacturing facility with one 483 observation. The observation was procedural in nature and corrected during the inspection itself.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2254.50 -123.40 (-5.19%)
11-May-2026 11:16 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1882.50
Dr. Reddys Lab 1290.55
Cipla 1339.80
Zydus Lifesciences 945.35
Lupin 2254.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×